Clinical Trial

A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Name: A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer — clinical trial record (NCT07241416)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This study aims to compare the efficacy and safety of rezvilutamide with enzalutamide in the treatment of patients with low-volume metastatic hormone sensitive prostate cancer.

Protocol Amendment History 1 change

notable Enrollment increased: 156 -> 206 participants 2026-05-12

Trial Details

NCT Number	NCT07241416
Lead Sponsor	Jiangsu HengRui Medicine Co., Ltd.
Conditions	Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Enrollment	206 participants
Start Date	2025-12-05
Primary Completion	2027-03 (estimated)
Study Completion	2028-09 (estimated)
Updated on ClinicalTrials.gov	2026-05-11